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Abstract
The P-glycoprotein multidrug transporter is a 170-kDa efflux pump which exports a diverse group of natural products,
chemotherapeutic drugs, and hydrophobic peptides across the plasma membrane, driven by ATP hydrolysis. The transporter
has been proposed to interact with its drug substrates within the membrane environment; however, much remains to be
learned about the nature and number of the drug binding site(s). The two nucleotide binding domains are responsible for
ATP binding and hydrolysis, which is coupled to drug movement across the membrane. In recent years, P-glycoprotein has
been purified and functionally reconstituted in amounts large enough to allow biophysical studies. The use of spectroscopic
techniques has led to insights into both its secondary and tertiary structure, and its interaction with nucleotides and drugs. In
this review, we will summarise what has been learned by application to purified P-glycoprotein of fluorescence spectroscopy,
circular dichroism spectroscopy and infra-red spectroscopy. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Resistance to multiple drugs is a serious problem
in the chemotherapeutic treatment of many human
cancers. One major cause of multidrug resistance
(MDR) is the overexpression in tumour cells of P-
glycoprotein (Pgp), a 170-kDa plasma membrane
protein. Pgp acts as an ATP-driven e¥ux pump for
a wide variety of hydrophobic natural products, che-
motherapeutic drugs, and peptides (for recent re-
views, see [1^3]). These compounds are structurally
diverse; the only common feature is their hydropho-
bic nature, and often, the presence of a positively
charged nitrogen atom. Pgp is a member of the
ABC (ATP-binding cassette) superfamily of proteins,
which are involved in the import and export of sub-
strates across membranes in organisms ranging from
procaryotes to mammals [4^6]. These proteins com-
prise a membrane-associated domain (in the case of
Pgp, believed to be made up of 12 K-helical mem-
brane-spanning segments), and two highly conserved
cytosolic nucleotide-binding (NB) domains which
couple ATP hydrolysis to substrate import or export.
Two classes of Pgp gene products exist ; the class I
and II isoforms are multidrug transporters, whereas
the class III isoform appears to be a lipid £ippase,
moving phosphatidylcholine (PC) from the inner to
the outer lea£et of the bile canalicular plasma mem-
brane. Pgp is expressed at the apical surface of the
intestinal epithelium, where it is responsible for the
low bioavailability of many drugs in the gut, and
in the endothelial cells of capillaries in the brain,
where it is a major contributor to the blood^brain
barrier.
The drug export function of Pgp can be blocked
by a class of compounds known as chemosensitisers,
modulators, or reversers [7]. Modulators interact di-
rectly with Pgp, and appear to compete with drugs
for the substrate binding site(s) on the protein. A
major challenge in the MDR ¢eld is to understand
the molecular basis for the action of these com-
pounds, and to design and develop more e¡ective
modulators for clinical application. Two of the best
studied modulators are the Ca2 channel blocker ve-
rapamil, and the immunosuppressant cyclosporin A,
which has been used successfully in clinical trials in
the treatment of paediatric cancers [8].
At the present time, very little information is avail-
able on the mechanism of action of any of the ABC
transporters. In particular, we need an in-depth
understanding of the way in which Pgp interacts
with such a large number of drugs, how the energy
provided by ATP hydrolysis at the NB domains is
used to translocate substrates across the membrane,
and the way in which modulators block drug e¥ux.
More detailed structural information is also needed
to assist in understanding the complex interactions
between the two NB domains and the membrane-
bound regions of the protein. Spectroscopic tech-
niques, especially £uorescence spectroscopy, are
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powerful tools for exploration of the structure and
function of membrane proteins. This review will give
an overview of recent work in which various spec-
troscopic techniques have been successfully applied
to provide novel information on both the structure
of Pgp, and its interactions with nucleotides, drugs
and modulators.
2. Nucleotide binding and hydrolysis
The NB domains of the ABC transporters are
characterised by the presence of three highly con-
served structural motifs; the Walker A and B se-
quences, and the so-called ABC signature sequence
[9]. The high resolution crystal structure of HisP has
clari¢ed the role of many of the residues within these
sequences in nucleotide binding and hydrolysis [10].
Of note are a highly conserved Lys residue within the
Walker A motif (GS/CGKS), which is directly in-
volved in binding the L-phosphate of ATP, and a
highly conserved Asp residue within the Walker B
motif (ILLLD), which serves to bind the Mg2 ion.
Mutations to either of these residues result in non-
functional Pgp. A de¢nitive role for the signature
sequence has not yet been elucidated.
Pgp is an unusual ATP-driven transporter, in that
it displays constitutive (basal) ATPase activity in the
apparent absence of substrates, a high Km for ATP
hydrolysis (in the range 0.4^0.8 mM), and a low
speci¢city for nucleotides. ATPase activity can be
stimulated by many drug substrates and modulators,
although some produce only inhibition. In general,
drugs produce a bimodal ATPase pro¢le, with stim-
ulation at low concentrations, and inhibition at high-
er concentrations. Sulfhydryl-reactive agents, such as
N-ethylmaleimide (NEM), covalently modify the two
Cys residues within the Walker A motif, leading to
inactivation of ATPase activity [11,12].
Addition to Pgp of ortho-vanadate (Vi), a com-
monly used ATPase inhibitor, in the presence of
ATP leads to trapping of the ADPWVi complex within
one catalytic site, with the complete abolition of
ATPase activity [13]. These observations led to the
proposal that Pgp operates by an alternating sites
mechanism [14,15]; that is, when one catalytic site
enters the transition state, the other is unable to do
so. Further vanadate trapping experiments showed
that mutations in the highly conserved Lys or Asp
residues of the Walker A and B motifs at either cat-
alytic site prevent even a single turnover of nucleo-
tide in the other non-mutant site, suggesting that the
two sites cannot independently carry out ATP hy-
drolysis in the intact molecule [16]. Thus, the two
NB domains show highly cooperative interactions.
However, the kinetics of ATP hydrolysis is strictly
Michaelis^Menten [17^19], in keeping with the pro-
posal that only one site is catalytically active at any
point in time.
Photolabelling of Pgp by 8-azido-ATP has often
been used as a measure of nucleotide binding. How-
ever, there are many drawbacks to the use of this
technique, including low site occupancy (concentra-
tions well below Km are usually used), and low label-
ling e⁄ciency (6 0.5%), which may change with pro-
tein conformation, for example, in the presence of
bound substrates. For these reasons, photolabelling
is not an appropriate quantitative tool to assess ATP
binding in, for example, mutational studies, where
the Kd for binding may have changed. To date,
only £uorescence spectroscopy has succeeded in
quantitating equilibrium binding of nucleotides to
Pgp (see below).
3. Puri¢cation and functional reconstitution of Pgp
The application of spectroscopic techniques to Pgp
is dependent on the availability of relatively large
amounts of puri¢ed, functionally active protein.
MDR Chinese hamster ovary cells selected for resis-
tance to colchicine [20] have proved to be a very
useful source material, and several groups have de-
veloped techniques for puri¢cation of functional Pgp
from plasma membrane vesicles derived from these
cell lines [17^19,21^23]. Dong et al. [24] also reported
puri¢cation of Pgp from various leukaemia and hep-
atoma cell lines that overexpressed the protein. Ex-
pression of histidine-tagged Pgp in heterologous sys-
tems, such as baculovirus-infected insect cells [25],
and the yeasts Saccharomyces cerevisiae [26] and Pi-
chia pastoris [16] resulted in acceptable yields of ac-
tive protein. Pgp has been successfully reconstituted
into proteoliposomes, where it displays both constit-
utive and drug-stimulated ATPase activity (see for
example, [17,21,27,28]), and ATP-dependent trans-
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port of chemotherapeutic drugs and hydrophobic
peptides [21,29^32].
4. Circular dichroism spectroscopic studies of Pgp
The most widely accepted model of Pgp topology,
in which the TM domains comprise 12 membrane-
spanning K-helices, has been con¢rmed by several
mapping studies [33,34]. Another model of Pgp struc-
ture, based on a double L-barrel motif, has been
proposed recently [35], and several studies have
also modelled the structure of the NB domains [36^
40]. To date, the only high resolution structural data
available for any member of the ABC superfamily is
the 1.5-Aî X-ray crystal structure of HisP, the ATP-
binding subunit of the histidine permease [10].
Circular dichroism (CD) spectroscopy can give
useful information on protein secondary structure,
as well as conformational changes that take place
on substrate binding. Sharma and Rose carried out
CD studies on the puri¢ed overexpressed recombi-
nant protein corresponding to the C-terminal NB
domain (NB2) of Pgp, both by itself, and as a fusion
product with maltose binding protein. They reported
that NB2 was a relatively well-folded protein, made
up of 14% K-helix, 42% L-strand, 20% L-turn and
23% other structures [41]. This is in striking contrast
to the secondary structure of HisP calculated from
the X-ray crystal structure and con¢rmed by CD
spectroscopy (40% K-helix, 23% L-strand) [10]. Since
there is a high level of sequence similarity between
HisP and the NB domains of Pgp, it seems reason-
able to expect extensive structural similarity between
the two proteins, and the discrepancy between the
two reports remains unresolved. Expressed NB2 dis-
played very low ATPase activity, and tended to ag-
gregate, which may re£ect some misfolding of the
protein, although it bound to ATP-agarose.
Dong et al. carried out a CD study on full-length
Pgp of human, rat and mouse origin, isolated from
overexpressing tumour cells [42]. The fully delipi-
dated protein, which displayed no ATPase activity
(function could be restored by reconstitution), was
examined in a dodecylmaltoside solution. The calcu-
lated overall secondary structure, 43% K-helix, 16%
L-strand, 15% L-turn, and 26% other structures,
agreed well with predictions made using modelling
methods. Variations in the shape of the CD spectra
for Pgps from the three species were attributed to
di¡erences in the N-linked oligosaccharides located
on the ¢rst extracellular loop. Mouse Pgp was under-
glycosylated compared to the rat and human pro-
teins, and enzymatic deglycosylation of the protein,
or tunicamycin treatment of the cells, abolished the
di¡erences in the CD spectra. Although glycosylation
of Pgp is not essential for its ATPase or transport
function, the N-linked oligosaccharides appear to in-
£uence the conformation of the protein in a subtle
way, perhaps by interacting with the TM domains.
5. Fourier transform infra-red spectroscopy of Pgp
Useful information on protein secondary structure
and conformational changes can also be provided by
Fourier transform infra-red (FTIR) spectroscopy.
Sonveaux and co-workers carried out an attenuated
total re£ection FTIR study of puri¢ed hamster Pgp
following reconstitution into asolectin proteolipo-
somes [43]. Secondary structure analysis based on
the amide I band indicated that, in the absence of
substrates, the protein consisted of 32% K-helix, 26%
L-strand, 29% L-turns, and 13% other structures.
These values do not agree well with those determined
by CD spectroscopy (see above). The overall second-
ary structure did not change signi¢cantly following
the addition of ATP, or the modulator verapamil, or
both.
Evidence for a conformational change on substrate
binding was obtained from the kinetics of 2H/1H ex-
change. Three classes of exchangeable amides were
identi¢ed, based on values of the period, T, of 1 min
(rapidly exchanging), 15 min (intermediate exchange
rate) and 2000 min (slowly exchanging). Overall, the
amide protons of Pgp exchanged poorly, indicating
that both the TM and extramembranous regions of
the protein have limited solvent accessibility, the for-
mer because they are protected by the bilayer, the
latter probably because they are folded into struc-
tured domains. Accessibility of the slowly exchanging
amide protons was increased by ATP binding, indi-
cating that a conformational change takes place. Ve-
rapamil alone did not alter the exchange rate, but
when added with ATP, a di¡erent type of conforma-
tional change took place, which resulted in protec-
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tion of some of the rapidly exchanging amides from
the solvent. Prior binding of ATP thus appears to be
required for a drug-induced conformational change,
perhaps readying the protein for transport.
6. Investigation of nucleotide binding to Pgp using
£uorescence spectroscopy
6.1. Nucleotide binding to expressed NB domains
Binding of £uorescent nucleotide analogues has
provided valuable information on the molecular ar-
chitecture and functional properties of the catalytic
sites within the NB domains of Pgp. Binding of
TNP-ATP/ADP and other £uorescent nucleotide
analogues was investigated by Di Pietro and co-
workers, using heterologously expressed recombinant
NB domains. These nucleotide derivatives have low
£uorescence in aqueous solution, which is greatly
enhanced upon binding within the hydrophobic en-
vironment of a protein catalytic site. NB2 was ex-
pressed in Escherichia coli in fusion with gluta-
thione-S-transferase, and puri¢ed both as a fusion
protein, and after thrombin cleavage [44]. Fluores-
cent TNP-ATP and TNP-ADP bound to both the
fused and puri¢ed NB2 with greatly enhanced £uo-
rescence. A blue shift in the emission maximum in-
dicated that the nucleotide was located in a hydro-
phobic environment. Titration of TNP-ATP and
TNP-ADP led to a concentration-dependent satura-
ble increase in £uorescence, and curve-¢tting was
used to extract values of the Kd for binding of 1.8
and 2.3 WM, respectively. These a⁄nities are V100-
fold higher than those for ATP and ADP, which are
around 0.4 mM (see below). Studies of the interac-
tion of these £uorescent nucleotides with the NB
domains of CFTR and ArsA (the ATP-binding sub-
unit of the E. coli arsenate transporter), also showed
that they bound with substantially higher a⁄nity
[45^47], likely as a result of the presence of the rel-
atively non-polar £uor. Baubichon-Cortay et al. [44]
also examined quenching of the intrinsic Trp £uores-
cence of NB2 by TNP-nucleotides. Again, concentra-
tion-dependent quenching was observed, and the es-
timated Kd values of 2^3 WM were similar to those
derived from £uorescence enhancement.
Expressed N-terminal NB domain (NB1) carrying
a hexahistidine tag also bound TNP-ATP and
MANT-ATP with high a⁄nity [48]. Covalent reac-
tion of the conserved Cys residue of the Walker A
motif with NEM did not abolish binding of the
MANT-ATP, but the binding a⁄nity was decreased
6-fold. More recently, an extended version of NB1
was expressed, which contained a Trp residue as an
intrinsic probe [49]. Using both enhancement of
MANT-ATP £uorescence and quenching of intrinsic
Trp £uorescence, this domain also bound £uorescent
nucleotides with a similar a⁄nity to the shorter ver-
sion of NB1. The ability of Pgp to bind several modi-
¢ed nucleotides with relatively high a⁄nity re£ects
the fact that the catalytic sites are somewhat non-
speci¢c [17].
It should be noted that in all studies where re-
combinant NB domains of Pgp were expressed, the
resulting proteins had extremely low ATPase cata-
lytic activity (100^2500-fold lower than full-length
native protein). The NB domains may need to inter-
act with the membrane-bound domains (e.g. the in-
tracellular loops) to fold properly, or if the alternat-
ing sites model is correct, one isolated NB domain
may be able to bind nucleotide, but unable to func-
tion catalytically without its partner. Because of the
low catalytic activity, it was not possible to examine
whether £uorescent nucleotides were e¡ective hydro-
lysis substrates.
6.2. Nucleotide binding to full-length native Pgp
Treatment of Pgp with 2-(4-maleimidoanilino)-
naphthalene-6-sulfonic acid (MIANS) resulted in se-
lective labelling of two Cys residues, one within each
Walker A motif of the NB domains, with concom-
itant loss of ATPase activity [22]. MIANS labelling
was blocked by ATP in a concentration-dependent,
saturable fashion with an IC50 value of 0.37 mM,
which is close to the Km for ATP hydrolysis. The
modi¢ed Cys residues are therefore located close to
the site of ATP binding within the NB domains (Fig.
1). This was con¢rmed by the high level of £uores-
cence resonance energy transfer (FRET) observed
between MIANS and bound TNP-ATP/ADP, which
resulted in almost complete quenching of the MI-
ANS emission at saturating concentrations of the
£uorescent nucleotides [50]. The bound MIANS dis-
played a 30-nm blue shift in the emission maximum,
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indicating that the local environment around the
modi¢ed Cys residues is relatively non-polar [22]. A
hydrophobic pocket may exist within the active site
to accommodate the adenine ring of the bound nu-
cleotide.
MIANS-Pgp displayed concentration-dependent
saturable quenching of the £uorescence on addition
of both ATP and ADP (Fig. 2A) [22]. This quench-
ing likely arises from a direct e¡ect of the bound
nucleotide on the quantum yield of the £uor. Fitting
of the experimental data to a hyperbolic equation
representing interaction with a single type of binding
site resulted in the extraction of Kd values for ATP
and ADP binding of V0.4 mM. This value is very
close to the Km for ATP hydrolysis by puri¢ed Pgp
and the Ki for its inhibition by ADP [17^19]. Thus
nucleotides are still able to bind to MIANS-Pgp,
with unchanged a⁄nity, following modi¢cation of
the two Cys residues (Fig. 1). However, ATP hydro-
lysis is completely inhibited, which suggests that the
introduction of the bulky £uor blocks one or more
steps in the catalytic cycle, perhaps as a result of
steric hindrance.
TNP-ATP was hydrolysed by puri¢ed Pgp with a
Km of 81 WM, although it was a poorer substrate
than ATP, with a 19-fold lower Vmax value [50]. Ki-
netic studies of inhibition of Pgp ATPase activity
indicated that TNP-ATP was a competitive inhibitor
of ATP hydrolysis, and TNP-ADP was a mixed in-
hibitor. Both TNP-ATP and TNP-ADP bound to
Pgp with high a⁄nity, with a blue shift in their emis-
sion maxima indicating a non-polar environment
within the active site [50]. The Kd values derived
from ¢tting a titration curve of the enhanced intrin-
sic £uorescence were 43 and 36 WM for TNP-ATP
and TNP-ADP, respectively, 10-fold lower than the
Kd for unmodi¢ed ATP. Almost identical Kd values
were obtained for native and MIANS-Pgp, and the
binding a⁄nities measured from quenching of the
MIANS £uorescence by FRET to the TNP moiety
were also similar.
Fig. 1. E¡ect of binding of ATP and drug substrates on the conformation of various domains of Pgp, as indicated by £uorescence
studies. Pgp is labeled with MIANS (indicated by asterisks) at two Cys residues, one within each of the Walker A motifs of the NB
domains. Accessibility of the MIANS group to the dynamic quenchers acrylamide and I3 changes on ATP binding, suggesting that a
conformational change takes place. Binding of nucleotides such as ATP leads to quenching of the £uorescence (vF1), likely via a di-
rect e¡ect on the quantum yield of the £uorophore. Binding of drug substrates also results in a conformational change in the NB do-
mains which causes MIANS quenching (vF2). Quenching of MIANS-Pgp induced by ATP and drugs appears to be independent and
additive, suggesting that Pgp does not require ordered addition of nucleotide and the transported substrate.
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6.3. Lipid modulation of nucleotide binding
Reconstitution of Pgp into bilayers of de¢ned
phospholipids at a wide range of lipid:protein ratios
[51] has allowed investigation of the e¡ects of lipid
£uidity and phase state on catalysis. Synthetic phos-
pholipids with single acyl chains, such as dimyristoyl-
PC (DMPC) and palmitoylmyristoyl-PC (PMPC),
have a well-de¢ned melting transition temperature,
Tm, which corresponds to a change in the bilayer
from the rigid gel phase to the £uid liquid-crystalline
phase. We reconstituted highly puri¢ed Pgp into bi-
layers of DMPC and PMPC, and investigated how
the change in phase state a¡ected the kinetic param-
eters for binding and hydrolysis of ATP [52]. The Km
for ATP hydrolysis by Pgp in detergent solution was
essentially unchanged at temperatures below and
above Tm, whereas the Km in bilayers of PMPC
and DMPC was substantially di¡erent (Table 1).
When the Kd values for ATP binding were quanti-
tated by £uorescence quenching, the a⁄nity was
found to be substantially higher in the £uid liquid-
crystalline phase (Table 1). Once again, the value of
Kd was unchanged over a wide temperature range for
Pgp in detergent solution.
Taken together, these results indicate that both
ATP binding and ATP hydrolysis by Pgp are modu-
lated by the biophysical state of the lipid bilayer,
independent of the change in temperature. Until re-
cently, the NB domains of the ABC transporters
were viewed as separately folded soluble domains.
However, the recent high resolution crystal structure
of HisP indicated that one arm of this protein is
likely embedded in the membrane. If the same holds
Fig. 2. Binding of nucleotides, substrates and modulators to Pgp as determined by quenching of MIANS-Pgp £uorescence. The com-
pound to be tested was titrated with puri¢ed MIANS-Pgp in the presence of soybean phospholipids at 22‡C. Percent quenching of the
£uorescence (vF/F0U100) was calculated relative to the £uorescence of MIANS-Pgp titrated with bu¡er alone. The continuous lines
represent the best ¢t of the data points (shown by the symbols) to an equation for binding to a single site [22,69,70]. (A) Binding of
ATP (b) and ADP (a). (B) Binding of the hydrophobic peptides cyclosporin A (8), reversin-121 (S), and beauvericin (W). (C) Bind-
ing of TMR (O), cis-£upentixol (R), and the AIDS protease inhibitor ritonavir (k). (D) Binding of daunorubicin (hexagons), verapa-
mil (F), and the cardiotonic steroid digitoxin (E). Data taken from [22,69,70] and R. Liu and F.J. Sharom, unpublished work.
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true for Pgp, the intimate association of the NB do-
mains with the membrane would readily explain the
modulation of their activity by lipid phase state. The
results of FRET studies also support the notion that
the NB domains are in close contact with the mem-
brane (see below and [53]).
6.4. Interaction of Pgp NB domains with £avonoids
Various £avonoids that occur naturally in fruits
and vegetables modulate drug e¥ux in MDR cells
[54,55]. The NB domains of Pgp appear to interact
directly with the £avonoid quercetin, which blocked
drug transport in a reconstituted system, likely by
inhibiting Pgp ATPase activity [56]. Several £avo-
noids (kaempferide, quercetin, genistein, apigenin,
naringenin, rutin) bound directly to the expressed
puri¢ed NB2 domain of Pgp, as shown by quenching
of the intrinsic Trp £uorescence [57]. The a⁄nity of
interaction of NB2 with £avonoids ranged from
4.5 WM for kaempferide to 34 WM for £avone. Occu-
pation of the £avonoid binding site by kaempferide
completely inhibited binding of MANT-ATP and
partially blocked ATP binding, indicating that the
two sites overlap. The ability of various £avonoids
to reverse MDR in the protozoan Leishmania tropica
was directly related to their a⁄nity for binding to
recombinant NB2 of the multidrug transporter in
this organism [58], suggesting that £avonoids may
be useful inhibitors for clinical application to MDR.
7. Investigation of drug and modulator binding to
Pgp using £uorescence spectroscopy
Protein mapping studies, together with site-di-
rected mutagenesis, have indicated that the drug
and modulator binding sites most likely lie within
the transmembrane (TM) regions of Pgp, especially
TM5, TM6, TM11 and TM12 [59,60]. Substantial
evidence supports the view that Pgp interacts with
its substrates within the bilayer matrix (reviewed in
[3,61]). The vacuum cleaner model of Pgp action
proposes that hydrophobic compounds partition
into the membrane, following which they are
pumped out into the extracellular space [62]. This
may take place via a £ippase-type mechanism (by
analogy to the class III Pgp), whereby drugs are
moved from the inner to the outer lea£et, followed
by equilibration with the aqueous phase. Much con-
troversy still exists concerning both the number and
nature of the drug binding sites within Pgp. Recent
reports support the idea of two non-identical drug
binding sites, which display positively cooperative
interactions and probably overlap [29,63,64],
although an additional site was recently proposed
[65].
Progress in this area has been hampered by the
di⁄culty of directly quantitating binding of hydro-
phobic drugs to Pgp. The dissociation constant for
binding of radiolabelled vinblastine has been deter-
mined for Pgp in membrane vesicles and in puri¢ed
form [23,66], and a quantitative assay for binding of
radiolabelled drugs to Pgp in permeabilised MDR
cells was also reported recently [67,68]. The more
general application of this direct approach for meas-
uring drug binding is limited by the availability of
radiolabelled substrates and the high backgrounds
that arise from partitioning of drug into lipid bi-
layers when using proteoliposomes. Drug binding
to Pgp has been most often assessed using photoaf-
¢nity labelling with the radiolabelled substrate ana-
logs 3H-azidopine and 125I-iodoarylazidoprazosin.
Although it is a useful qualitative indicator of drug
Table 1
Kinetic parameters for ATP binding and hydrolysis by Pgp in lipid bilayers and CHAPS solution
ATP hydrolysis Km (mM) ATP binding Kd (mM)
Gel Liquid crystal Gel Liquid crystal
PMPC 0.34 þ 0.11 1.09 þ 0.25 0.59 þ 0.06 0.30 þ 0.03
DMPC 0.46 þ 0.11 0.74 þ 0.10 0.49 þ 0.04 0.40 þ 0.03
CHAPS 0.29 þ 0.06 0.33 þ 0.05 0.20 þ 0.02 0.18 þ 0.01
The same Pgp or reconstituted proteoliposome preparation was analyzed at two di¡erent temperatures, either above or below the Tm
for DMPC (20 and 28‡C) or PMPC (23 and 33‡C). The errors given show the goodness of ¢t of the data (from [52]) by non-linear re-
gression to either the Michaelis^Menten equation (Km) or an equation for binding to a single site (Kd).
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binding, photolabelling is unsuited to quantitative
measurements, for the reasons mentioned earlier.
Our laboratory has developed a £uorescence
quenching method that can measure equilibrium
binding of substrates to puri¢ed Pgp, and provide
an estimate of the dissociation constant for binding.
As described earlier, Pgp can be labelled at the two
Walker A Cys residues with the £uorophore MI-
ANS. Addition of drugs to MIANS-Pgp in the pres-
ence of lipid leads to concentration-dependent
quenching of the £uorescence. The quenching titra-
tion can be ¢tted to a binding equation, providing a
quantitative estimate of Kd [22]. Quenching of the
£uorescence of the MIANS group in the catalytic
site by binding of drug to the TM regions presum-
ably arises from conformational coupling between
the two domains of the protein. In other words,
drug binding to a site (or sites) within the TM seg-
ments of Pgp sends a signal to the NB domains,
producing a conformational change at the active
site which alters the local environment of the MI-
ANS probe (Fig. 1). This conformational communi-
cation is re£ected in the stimulation (or inhibition) of
ATPase activity by drugs, and must play an essential
role in the coupling of ATP hydrolysis to drug trans-
port. The £uorescence quenching seen on ATP bind-
ing is additive with that caused by drug binding [22],
and suggests that nucleotides and substrates bind to
Pgp independently, and in a random order (Fig. 1).
We have applied the MIANS quenching technique to
estimate the Kd value for over 60 substrates and
modulators [22,61,69,70]. Quenching titrations for
some of these compounds are shown in Fig. 2B^D,
and Table 2 gives the Kd values for some represen-
tative classes of non-peptide and peptide-based
drugs. To date, the range of measured Kd values
covers a s 10 000-fold range, from 24 nM to 260 WM.
As indicated by MIANS-Pgp quenching, sub-
strates that interact directly with the protein include
chemotherapeutic drugs, such as vinblastine, dauno-
rubicin, and paclitaxel, as well as modulators, such
as verapamil, reserpine, and £upentixol. HIV pro-
tease inhibitors are a newly identi¢ed group of Pgp
substrates of clinical importance [71^73]. We found
that three compounds in this class, ritonavir, indina-
vir, and nel¢navir, all interacted with the protein
with a⁄nities in the sub-WM range. Many linear pep-
tides interacted with Pgp, including simple tripepti-
des (ALLN, ALLN, leupeptin), and modi¢ed tripep-
tides, such as the reversins, which are highly e¡ective
MDR modulators [70]. Cyclic species, such as vali-
nomycin, the related molecule beauvericin, and the
modulator cyclosporin A also bound to Pgp with
high a⁄nity [69]. Triton X-100 was a high a⁄nity
substrate, in line with a report that a related non-
ylphenol ethoxylate surfactant was the major Pgp
substrate excreted in human urine [74]. In contrast,
a group of surfactants that reverse MDR (Cremo-
phor EL, Solutol HS, Tween-80) did not quench
MIANS-Pgp £uorescence (R. Liu and F.J. Sharom,
unpublished data), and probably do not interact with
the protein directly. The modulatory action of this
Table 2
A⁄nity of binding of drugs, peptides and modulators to Pgp as determined by £uorescence quenching
Non-peptide drugs and modulators Peptide-based drugs and modulators
Ligand Kd (WM) Ligand Kd (WM)
Colchicine 158 ALLN 138
Naloxone 54.2 ALLM 83.1
Digitoxin 15.9 Leupeptin 77.6
Daunorubicin 10.5 Pepsinostreptin 62.8
Tri£uoperazine 7.7 Pepstatin A 35.8
Tamoxifen 4.1 Chymostatin 32.7
Verapamil 2.4 N-boc-deacetyl-leupeptin 11.3
Ritonavir 0.78 NAc-FnorLRF-amide 10.3
Vinblastine 0.77 Valinomycin 0.78
Reserpine 0.73 Beauvericin 0.36
Topotecan 0.50 Cyclosporin A 0.20
Triton X-100 0.37 Reversin-205 0.14
Paclitaxel (taxol) 0.037 Reversin-121 0.077
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group of compounds may be related to their ability
to £uidise membranes, and increase the rate of trans-
bilayer £ip-£op of drug substrates [3]. The cardioton-
ic steroids digitoxin, digoxin, digitoxigenin and di-
goxigenin, which stimulate Pgp ATPase activity
[75], were also substrates, with Kd values ranging
from 16 to 263 WM. Several modulators that were
developed for clinical use, including PSC833,
LY335979, GF120918, and CP-100356, displayed
very high a⁄nities for interaction with Pgp, in the
range 24^75 nM. Many of these compounds are cur-
rently in various stages of clinical or pre-clinical test-
ing.
All of the compounds that interacted with Pgp in
the MIANS quenching assay also modulated drug
transport by Pgp in a plasma membrane vesicle sys-
tem [29,76,77]. The majority of drugs competed for
Pgp-mediated colchicine transport in a concentra-
tion-dependent manner, allowing the extraction of
an IC50 value for 50% inhibition of transport. The
Kd value for binding of a compound to Pgp was
highly correlated with its IC50 value for inhibition
of colchicine transport. Fig. 3 shows such a correla-
tion for 47 Pgp substrates in a wide variety of struc-
tural categories. The fact that this correlation ex-
tends over almost four orders of magnitude (Kd
from 24 nM to 160 WM) suggests that Pgp transports
all its substrates by a common mechanism. These
results also indicate that high binding a⁄nity is an
important criterion in the design of MDR modula-
tors for clinical application.
Some compounds gave rise to stimulation of col-
chicine transport (see for example [29,63]). Shapiro
and Ling suggested that this e¡ect may arise from
positively cooperative interactions between di¡erent
drug binding sites within Pgp, denoted the R site and
the H site [63]. Evidence for the existence of two
non-identical binding sites for 125I-iodoarylazidopra-
zosin has also been reported [64]. Thus, there is sub-
stantial evidence to suggest that Pgp contains two
substrate binding sites with di¡erent a⁄nities, and
that a particular drug may interact with one or
both of these sites. We used MIANS-Pgp quenching
to examine the binding of three representative trans-
ported compounds, the chemotherapeutic drugs vin-
blastine and daunorubicin, and the chemosensitiser
verapamil [78]. For both vinblastine and verapamil,
biphasic quenching curves were observed, suggesting
the existence of two drug binding sites with di¡ering
a⁄nities (Fig. 4). Data were ¢tted by non-linear re-
gression to an equation for interaction of the drug
with either a single binding site of a⁄nity Kd1, or two
binding sites, one with high a⁄nity (Kd1), the other
with lower a⁄nity (Kd2). Our data are consistent
with the report of biphasic, two-a⁄nity binding to
Pgp of 3H-verapamil and several other drugs, includ-
ing vinblastine, vincristine, quinidine, rhodamine-123
and chlorpromazine, but only single a⁄nity binding
for daunorubicin [67]. In the proposed two-site mod-
el [63], daunorubicin was postulated to interact only
with the R-site, and vinblastine was proposed to in-
teract with both sites. Our results support such a
model, in that we observed single-site binding for
daunorubicin and two-site binding for vinblastine.
Given the fact that most Pgp substrates are hydro-
phobic and probably partition into the membrane
before they interact with the transporter, we might
expect that the nature of the host lipid bilayer would
play an important role in modulating drug binding.
The high a⁄nity component of drug binding to pu-
ri¢ed Pgp was indeed markedly dependent on several
di¡erent properties of the lipid environment sur-
Fig. 3. Correlation of the Kd for binding to puri¢ed Pgp with
the IC50 for inhibition of colchicine transport for many drugs
and chemosensitisers. Kd values for 47 compounds were deter-
mined by £uorescence quenching of MIANS-Pgp. IC50 values
represent the concentration of compound causing 50% inhibi-
tion of [3H]colchicine transport into CHRB30 plasma membrane
vesicles. The data were ¢tted to a straight line by linear regres-
sion r = 0.84). Data taken from [22,69,70,76,77] and R. Liu, P.
Lu and F.J. Sharom, unpublished work.
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rounding the protein [78]. These experiments were
made possible by the fact that our preparation of
puri¢ed Pgp, unlike several others reported in the
literature [17,18,23,24] is entirely free of exogenously
added lipids. Changing the lipid headgroup from
choline to serine to ethanolamine, with similar acyl
chains, resulted in very large changes in the value of
Kd1. All the drugs bound to Pgp with the highest
a⁄nity in egg PC; in the case of vinblastine, the
binding a⁄nity was 17-fold higher in egg PC com-
pared to egg PE. Drug binding was also greatly af-
fected by the nature of the lipid acyl chains. On
changing the acyl chain composition from unsatu-
rated (egg PC) to 14C and 16C saturated (DMPC
and DPPC, respectively), large changes in binding
a⁄nity of up to 15-fold were noted. For all three
drugs, binding a⁄nity was highest in egg PC and
lowest in DPPC, with DMPC displaying intermedi-
ate values. The values of Kd1 in egg PC relative to
DPPC were over 6-fold lower for vinblastine, and
15-fold lower for verapamil. Daunorubicin binding
a⁄nity showed a smaller e¡ect, with a 1.6-fold de-
crease in egg PC relative to DPPC. The physical state
of the bilayer also modulated drug binding. All drugs
bound to Pgp with higher a⁄nity when the protein
was present in gel phase DMPC (at 20‡C) relative to
Fig. 4. Fluorescence quenching curves for binding of vinblastine (A^C) and verapamil (D^F) to puri¢ed MIANS-labelled Pgp at 22‡C
in the presence of 0.5 mg/ml egg PC (A,D), DMPC (B,E) and DPPC (C,F). The data points (shown by the symbols) represent the
mean þ range (n = 2). Where not visible, error bars are included within the symbols. The biphasic binding curves are made up of data
points from a high a⁄nity (b) and a low a⁄nity (a) region. The continuous lines represent the computer-generated ¢t of the data
points in the high and low a⁄nity regions to non-interacting sites of a⁄nity Kd1 and Kd2, respectively. Only the upper part of the ¢t-
ted curve is shown for the low a⁄nity region of the plots. Taken from [78] with permission.
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liquid-crystalline DMPC (at 30‡C). The Kd1 values
for vinblastine were 2.5-fold lower when the lipid
was in the gel state, whereas the Kd1 values for bind-
ing of verapamil and daunorubicin were 4-fold and
3-fold lower, respectively. Thus, substrate binding to
Pgp is modulated by the lipid headgroup, the nature
of the acyl chains, and the phase state of the bilayer.
The Pgp ATPase drug stimulation/inhibition pro¢les
were also altered in di¡erent lipids, in a manner con-
sistent with the observed changes in binding a⁄nity.
Egg PC, DMPC and DPPC have the same head-
group, so the observed di¡erences in drug binding
a⁄nity cannot be attributed to altered electrostatic
interactions, etc. We wondered whether the modula-
tion of binding a⁄nity by the acyl chain composition
re£ected the ability of the drugs to partition into
bilayers of the di¡erent PCs. Since the vacuum
cleaner model of Pgp action proposes that it extracts
substrates from the lipid bilayer, their lipophilicity
becomes potentially important. A higher lipid^water
partition coe⁄cient (Plip) for a particular drug would
have the e¡ect of increasing the e¡ective substrate
concentration in the lipid phase, thereby increasing
the apparent binding a⁄nity (Fig. 5). When we
measured the Plip values for distribution of the drugs
between bilayers of egg PC, DMPC and DPPC, and
water, we noted relatively large di¡erences. All three
drugs showed the highest partitioning into egg PC,
less partitioning into DMPC, and substantially lower
partitioning into DPPC. Plip for verapamil was most
sensitive to the lipid bilayer composition, varying al-
most 20-fold from egg PC to DPPC. Vinblastine and
daunorubicin showed 3-fold and 3.2-fold di¡erences
in Plip, respectively, between egg PC and DPPC.
When the Plip values were compared to the high
a⁄nity Kd values for the three drugs in the same
lipids (Fig. 6), it was observed that the binding a⁄n-
ity was highly correlated with the partition coe⁄-
Fig. 5. The a⁄nity of substrate binding to MIANS-Pgp is di-
rectly related to the lipid^water partition coe⁄cient of the drug.
A substrate with a high value of Plip will have a high e¡ective
concentration within the lipid bilayer, and a correspondingly
high binding a⁄nity is measured (low Kd value), whereas an-
other substrate with a low value of Plip will have a lower e¡ec-
tive concentration within the lipid bilayer, and a correspond-
ingly lower binding a⁄nity (higher Kd value).
Fig. 6. Correlation between the Pgp binding a⁄nity (Kd) and
the lipid^water partition coe⁄cient (Plip) for (A) vinblastine,
(B) verapamil, and (C) daunorubicin, in liposomes of egg PC,
DMPC and DPPC. The solid line represents the best ¢t of the
date to a straight line by linear regression: (A) r = 0.9996,
slope =31.70; (B) r = 0.9906, slope =30.89; (C) r = 0.742,
slope =30.33. Taken from [78] with permission.
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cient, i.e. as Plip increased, Kd1 decreased (binding
a⁄nity increased). These results provide support for
the vacuum cleaner model of Pgp action, and suggest
that the protein does in fact recognise its transport
substrates in the context of the lipid bilayer (Fig. 5).
8. Fluorescence studies of drug transport by Pgp
The process of drug transport by Pgp di¡ers from
that of most other ATP-driven transporters in that
its hydrophobic substrates have a relatively high rate
of passive di¡usion across the membrane compared
to ions and small polar substrates. As a consequence,
the observed (net) rate of drug transport by Pgp
represents a balance between two opposing proc-
esses; active pumping by Pgp up a concentration
gradient, and passive di¡usion of drug across the
membrane down the concentration gradient. Thus,
both the ‘true’ rate of drug transport by Pgp, and
the opposing rate of passive di¡usion through a lipid
bilayer, are central to the formation of a concentra-
tion gradient across the membrane, and the observa-
tion of cellular resistance to the drug.
Quantitative characterisation of the kinetics of
substrate transport by Pgp in a simple, easily manip-
ulable model system will allow detailed dissection of
its mechanism of action. Our previous studies on
drug and peptide transport by Pgp in plasma mem-
brane vesicles and proteoliposomes employed rapid
¢ltration, using a ¢xed-time equilibrium approach
[21,29,76,77]. Since drug uptake was very fast, trans-
port became non-linear after 6 1 min, so true kinetic
parameters could not be determined. The rapid ¢l-
tration technique is also time-consuming, and re-
quires large amounts of both proteoliposomes and
radiolabelled substrate. Real-time £uorescence-based
assays can generate kinetic data much more rapidly,
and are much more economical in the use of materi-
als.
Several £uorescent compounds are transport sub-
strates for Pgp in intact MDR cells, including the
acetoxymethyl esters of Ca2- and pH-sensitive
dyes, such as calcein, Fura-2, and BCECF [79,80],
a £uorescent derivative of verapamil [81], and vari-
ous rhodamine dyes [82]. In plasma membrane
vesicles from the MDR cell line CHRB30, the £uo-
rescent substrates rhodamine-123 [83], Hoechst
33342 [84], and LDS-751 [85] have all been used to
measure initial rates of transport. In the only pub-
lished study to date of initial rates of substrate trans-
port by reconstituted Pgp, Shapiro and Ling used
Hoechst 33342 as the substrate [32]. This dye has
negligible £uorescence in aqueous solution, and dis-
plays enhanced £uorescence following partitioning
into the lipid bilayer, so that the monitored decrease
in intensity corresponded to Pgp-mediated pumping
of the dye out of the bilayer. The measured rate of
Hoechst transport was extremely slow, and since the
vesicles were not sealed, it was not possible to estab-
lish a substrate concentration gradient. In addition,
because the dye concentration in the lipid phase was
unknown, analysis of kinetic parameters could not be
carried out.
Our laboratory has recently developed a continu-
ous £uorescence-based assay that allows determina-
tion of the kinetic parameters for transport by puri-
¢ed Pgp in proteoliposomes of a de¢ned
phospholipid. We chose the rhodamine dye tetrame-
thylrosamine (TMR), which is a high a⁄nity Pgp
substrate (Kd = 0.7 WM). Addition of 1 mM ATP
and a regenerating system to proteoliposomes con-
taining Pgp in the presence of 1 WM TMR led to a
rapid drop in TMR £uorescence, until a new lower
steady-state level was reached (Fig. 7A,B). This de-
crease in intensity arises from transport of TMR into
the vesicle interior, where it loses its £uorescence
(Fig. 8A). This phenomenon was previously noted
for rhodamine-123, and has been applied to the
measurement of dye transport in plasma membrane
vesicle systems in yeast and mammalian cells [63,86].
The initial rate of the £uorescence decrease was esti-
mated by intensity measurements made every 1 s for
about 20 s (Fig. 7C). TMR accumulates in the vesicle
interior during the transport process, as indicated by
the fact that the £uorescence decrease was osmoti-
cally sensitive and disrupted by detergent. Only back-
ground changes in £uorescence intensity were ob-
served when ATP was replaced with AMP, if
vanadate was added prior to ATP, or if Pgp was
denatured by heat treatment. Addition of vanadate
(Fig. 7A) or verapamil (Fig. 7B) following establish-
ment of the new steady-state resulted in restoration
of the TMR £uorescence to close to its original level.
These agents inhibit transport by Pgp, and will thus
lead to e¥ux by passive di¡usion of a compound
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accumulated in the proteoliposome lumen (Fig. 8). It
was possible to estimate the initial rate of restoration
of the £uorescence after addition of inhibitor or
modulator, which represents the rate of passive dif-
fusion of TMR out of the proteoliposome lumen,
driven by the concentration gradient previously built
up by Pgp (Fig. 7D). These experiments directly
demonstrated that Pgp generates a substrate concen-
tration gradient by inward-pumping of substrate into
reconstituted proteoliposomes (Fig. 8A). This gra-
dient subsequently collapses if the pumping action
of the transporter is inhibited by addition of vana-
date or a modulator to the vesicle exterior (Fig. 8B).
The ability of the real-time assay to measure the
initial rate of TMR transport allowed characterisa-
tion for the ¢rst time of the kinetic parameters for
substrate transport by Pgp in proteoliposomes. The
initial rate of TMR transport was determined at a
¢xed TMR concentration of 1 WM, and increasing
concentrations of ATP up to 1.0 mM (Fig. 9A).
Data were ¢tted to the Michaelis^Menten equation,
leading to an estimate of 0.48 mM for the Km of
ATP for drug transport, which is very close to
both the Km for hydrolysis of ATP by this Pgp prep-
aration (V0.4 mM, see [19,52]), and the Kd for bind-
ing of ATP to the catalytic site, as determined by
£uorescence quenching of MIANS-labelled Pgp (0.4
mM, Fig. 2A). The initial rate of TMR transport was
measured at increasing TMR concentrations up to
2.5 WM, at a ¢xed ATP concentration of 1 mM
(Fig. 9). The resulting data ¢tted well to the Michae-
lis^Menten equation, and the Km for TMR transport
was estimated to be 0.3 WM. Thus reconstituted Pgp
obeyed Michaelis^Menten kinetics with respect to
both ATP and TMR. Verapamil both inhibited the
net rate of TMR transport, and prevented the gen-
eration of a substrate concentration gradient. We are
currently using this system to examine competition
Fig. 7. Real-time £uorescence measurements of TMR transport into reconstituted proteoliposomes containing Pgp. A 450-Wl aliquot
of proteoliposomes containing 10^20 Wg of Pgp was equilibrated with 1 WM TMR in transport bu¡er at 27‡C for V200 s. TMR
transport was initiated (indicated by the arrow) by addition of bu¡er containing ATP (¢nal concentration 1 mM) and an ATP regen-
erating system, followed by mixing for 10 s. Fluorescence intensity (Vex = 550 nm, Vem = 575 nm) was measured at 1-s intervals for
about 150 s, until equilibrium was approached. At this time, vanadate (A; ¢nal concentration 100 WM) or verapamil (B; ¢nal concen-
tration 20 WM) was added as indicated by the arrow, and after mixing for 10 s, £uorescence intensity data were collected for a further
100^150 s. Fluorescence data collected immediately after addition of ATP or vanadate are shown in C and D, respectively.
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between substrates and modulators, and lipid modu-
lation of TMR transport.
Studies with £uorescent dyes have also provided
information on the location of the substrate within
the membrane bilayer during the transport process.
Using a diphenylhexatriene derivative (TMA-DPH)
as a substrate, the Lactococcus multidrug transport-
ers LmrA and LmrP have both been shown to ex-
trude their substrates from the inner lea£et of the
cytoplasmic membrane [87,88]. A biphasic increase
in £uorescence intensity was noted on addition of
TMA-DPH to membrane vesicles, re£ecting fast en-
try of the dye into the outer lea£et followed by slow
£ip-£op to the inner lea£et of the membrane. The
initial rate of TMA-DPH extrusion correlated with
the amount of probe associated with the inner lea£et,
demonstrating that these transporters function as hy-
drophobic vacuum cleaners. In similar experiments,
Fig. 8. Generation (A) and collapse (B) of a TMR gradient in
reconstituted proteoliposomes containing puri¢ed Pgp. (A) Gra-
dient generation. Transporters facing inwards have NB domains
accessible at the exterior surface of the lipid bilayer. Hydrolysis
of ATP powers pumping of TMR into the vesicle lumen, where
it loses its £uorescence, resulting in a time-dependent decay of
the £uorescence intensity (Fig. 7). Uphill pumping of TMR by
Pgp generates a TMR concentration gradient. When the steady-
state is reached (the £uorescence intensity reaches a plateau, see
Fig. 7), inward transport of TMR by Pgp is balanced by out-
ward passive di¡usion of TMR down its concentration gra-
dient. Transporters facing outwards, with their NB domains in
the vesicle lumen, have access to ATP, and do not contribute
to substrate transport or ATP hydrolysis. (B) Gradient collapse.
Inward pumping of TMR by Pgp is blocked by addition of ei-
ther vanadate (which inhibits Pgp ATPase activity) or MDR
modulators, such as verapamil (which compete for substrate
binding). The TMR gradient built up in A then collapses by
passive di¡usion of the compound down the concentration gra-
dient, resulting in recovery of the £uorescence intensity (Fig. 7).
Fig. 9. Dependence of the initial rate of TMR transport in Pgp
proteoliposomes on ATP and TMR concentrations. (A) TMR
transport was measured at a ¢xed TMR concentration of 1
WM, and varying concentrations of ATP. (B) TMR transport
was measured at a ¢xed ATP concentration of 1 mM, and
varying concentrations of TMR. Two independent measure-
ments of the initial rate (b, 8) were conducted. Data points
were ¢tted to the Michaelis^Menten equation, as shown by the
solid line, and the Km values were estimated.
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it was reported that Pgp expelled Hoechst 33342 and
LDS-751 from the cytoplasmic lea£et of plasma
membrane vesicles from MDR cells [84,85].
9. Structural studies of Pgp using £uorescence
spectroscopy
Dynamic quenching studies can provide useful in-
formation on aqueous accessibility, as well as con-
formational changes accompanying substrate bind-
ing. The use of quenching agents with di¡erent
charges can also give an indication of the charge
and polarity of the local environment. In the case
of MIANS-Pgp, the high e⁄ciency of energy transfer
to bound TNP-ATP indicated that the MIANS
group on the Walker A Cys residues was located
very close to the site of nucleotide binding. We car-
ried out quenching studies of MIANS-Pgp using the
neutral quencher acrylamide, and the charged
quenchers iodide ion, I3, and cesium ion, Cs [50].
The Stern^Volmer plots obtained for quenching were
linear for all three agents, indicating that the two
bound MIANS groups are in virtually identical en-
vironments. The Ksv value for acrylamide was 4.5-
fold lower than that measured for MIANS linked
to dithioerythritol (DTE), leading to the conclusion
that the labelled Cys residues are largely buried with-
in the protein structure. Cs quenched MIANS-Pgp
poorly compared to MIANS-DTE, whereas I3
quenched MIANS-Pgp as e¡ectively as MIANS-
DTE. These results suggested the presence of positive
charge in the vicinity of the £uor, such that a neg-
atively charged quencher is attracted into that re-
gion, whereas a positively charged quencher is re-
pelled. The major contributor to this positive
charge is likely the highly conserved Lys residue of
the Walker A motif, which lies two positions down-
stream of the Cys residues where the MIANS group
is located. The crystal structure of HisP showed that
this Lys residue plays a major role in nucleotide
binding by coordinating to the L-phosphate of ATP
within the active site [10].
Addition of ATP to MIANS-Pgp gave rise to
changes in the Ksv values for all three quenchers
[50], providing evidence for a conformational change
on nucleotide binding (Fig. 1) Acrylamide quenched
more poorly in the presence of 1 mM ATP, which
suggested that the solvent accessibility of the active
site is reduced on nucleotide binding. Alternatively,
ATP may physically block access of the quencher to
the £uorophore. Following ATP binding, Cs was a
better quencher, and I3 a much poorer quencher,
suggesting that the charge on the Lys residue is
screened by the bound nucleotide.
FRET is a valuable technique which can be used
as a spectroscopic ruler to estimate the distance sep-
arating two £uorophores. Its application to the
Ca2-ATPase has led to the generation of a 3-dimen-
sional map of various residues within the protein, as
well as their placement relative to the membrane sur-
face [89]. FRET involves the non-radiative transfer
of energy from the excited state of a £uorescent do-
nor to a £uorescent acceptor. The main criterion for
such energy transfer is good overlap between the
£uorescence emission spectrum of the donor and
the absorption spectrum of the acceptor, and a do-
nor^acceptor separation of between 10 and 75 Aî .
The e⁄ciency of energy transfer depends on the sep-
aration distance, according to the equation,
R = R0(E3131)1=6, where R0 is the distance at which
the energy transfer e⁄ciency is 50%. R0 is a constant
for a particular donor^acceptor pair, and can be cal-
culated from the spectral overlap and the quantum
yield of the donor.
We recently carried out the ¢rst application of
FRET to mapping the structure of the Pgp molecule
[53]. Highly puri¢ed Pgp was labelled on the two Cys
residues within the catalytic sites with either MIANS,
or the £uor 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole
(NBD-Cl). Each labelled Pgp molecule was reconsti-
tuted into lipid bilayer vesicles containing a suitable
£uorescent lipid acceptor in which the £uorophore
was on the headgroup, positioned in the interfacial
region of the bilayer. MIANS-Pgp was co-reconsti-
tuted with NBD-phosphatidylethanolamine (PE),
and NBD-Pgp with Lissamine-rhodamine B
(LRhoB)-PE. Excitation of MIANS-Pgp in the pres-
ence of increasing amounts of NBD-PE resulted in a
progressive decrease in MIANS emission, and a cor-
responding increase in emission characteristic of the
NBD moiety, indicating that energy transfer had tak-
en place. Similarly, FRET was observed to take place
from NBD-Pgp to LRhoB-PE. The distance separat-
ing the donor £uorophore within the catalytic site
from the interfacial region of the bilayer was esti-
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mated by ¢tting the loss of donor £uorescence to two
di¡erent theoretical models. Each donor^acceptor
pair gave similar estimates of the separation distance,
in the range 31^35 Aî , which provides con¢dence in
their validity. In addition, the data ¢tted very well to
the models, suggesting that the two £uors within the
NB domains are roughly equidistant from the mem-
brane surface. The distances obtained by FRET sug-
gest that the NB domains of Pgp are in close contact
with the membrane or, by analogy to HisP, em-
bedded in it.
The alternating sites model of Pgp function raises
the question of whether the two NB domains are
identical in terms of their structure and function.
The biochemical and spectroscopic evidence collected
to date indicates that this is the case. The kinetics of
ATP hydrolysis gave a single Km value, and binding
of ATP, ADP and £uorescent nucleotides showed no
evidence of heterogeneity. The £uorescence emission
spectra of both MIANS-Pgp and NBD-Pgp also
gave no indication of more than one type of environ-
ment, and the FRET experiments described above
led to the conclusion that both catalytic sites are
located symmetrically with respect to the membrane
surface. Taken together, these data suggest that the
two NB domains are probably both structurally and
functionally identical, so that each contributes
equally to an alternating sites mode of action.
Recent work in our laboratory has used FRET to
map the separation between the two catalytic sites of
Pgp (Q. Qu and F.J. Sharom, unpublished data). The
Walker A Cys residue of one NB domain was la-
belled with the donor £uor MIANS, and the Cys
in the other with the acceptor NBD. FRET experi-
ments indicated a very high level of energy transfer,
resulting in quenching of the donor of over 95%. The
separation distance between the two £uors was esti-
mated to be V17Aî , which suggests that the two
catalytic sites are located relatively close together.
Fig. 10 combines information obtained from elec-
tron microscopy and FRET studies of Pgp with the
known X-ray crystal structure of HisP, to produce a
low resolution model of Pgp structure. Based on the
low resolution structure obtained by electron micro-
scopy, Pgp was proposed to be a cylindrical molecule
about 100 Aî wide and 80 Aî deep [90]. The asterisks
indicate the placement of the various £uors within
the catalytic sites, and on the lipid headgroups. The
organisation of the two NB domains is assumed to
be patterned after the HisP dimer, with each domain
consisting of two arms, one of which is embedded in
the membrane. The two NB domains may be in con-
tact with each other, as might be expected if they are
to interact cooperatively in an alternating fashion.
Recent evidence (discussed above) points to the ex-
istence of two non-identical sites at which drugs and
modulators bind within the Pgp molecule (indicated
in Fig. 10 as D1 and D2). At the moment, we know
little about the distance between these binding sites,
or their proximity to the NB domains which provide
the energy to power transport of the bound drug. It
may be possible to answer these questions using
FRET between £uorescent drug analogues and a £u-
orophore bound at the catalytic sites. By using sev-
eral di¡erent drugs and modulators, and estimating
the distance of the binding site for each from the
catalytic site, it may also be possible to determine
whether they bind to spatially distinct locations. Flu-
orescence studies such as these could be used to build
a low resolution map of the Pgp molecule which, in
the absence of high resolution structural information,
could prove very useful in understanding how the
protein functions.
Fig. 10. Proposed model of Pgp structure from FRET studies.
The protein is depicted as a cylindrical structure 100 Aî wide
and 80 Aî deep, with two L-shaped NB domains partially em-
bedded in the membrane. The £uorescent probes employed in
FRET studies (bound to NB1, NB2, and the lipid headgroups)
are indicated by asterisks. FRET analysis indicates that the
probes within the catalytic sites are located V33 Aî from the
interfacial region of the membrane, and are separated from
each other by V17 Aî . D1 and D2 indicate the two putative
drug binding sites, thought to be located within the TM region
of the protein, on the cytosolic side of the membrane.
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10. Concluding remarks
In summary, considerable progress has been made
in the past few years in understanding the molecular
architecture and function of the Pgp molecule. The
development of methods for functional puri¢cation
of substantial amounts of the protein has allowed
researchers to study it using various spectroscopic
and biophysical techniques. Fluorescence spectros-
copy, in particular, has allowed the direct quantita-
tion of binding a⁄nity for nucleotides, drugs and
modulators, and has furnished evidence for confor-
mational changes in Pgp arising from binding events.
The application of FRET may generate a low reso-
lution map of locations of the substrate binding sites
within the protein. Information on secondary struc-
ture and conformation has been provided by both
CD and FTIR spectroscopy. The continued applica-
tion of spectroscopic techniques promises to yield
additional information that may be applied to the
design of new approaches to suppress Pgp-mediated
drug e¥ux in human tumours.
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